Department of Neurology, Shengli Oilfield Central Hospital, Dongying 257034, Shandong, China.
Biomark Med. 2020 May;14(7):539-548. doi: 10.2217/bmm-2019-0455. Epub 2020 May 28.
This study aimed to investigate the clinical significance of microRNA-33b (miR-33b) in glioma patients and its biological function in tumor progression. Expression of miR-33b was measured using quantitative real-time RT-PCR. Diagnostic and prognostic values of miR-33b were assessed by the receiver operating characteristics curve and Kaplan-Meier (KM) survival assay. The functional role of miR-33b was further analyzed. Expression of miR-33b in glioma patients and cells was decreased. Expression of miR-33b had high diagnostic accuracy and could predict a poor prognosis. Overexpression of miR-33b led to suppressed glioma cell proliferation, migration and invasion. Decreased expression of miR-33b serves a promising biomarker in the diagnosis and prognosis of glioma, and may be a potential therapeutic target.
本研究旨在探讨 microRNA-33b(miR-33b)在脑胶质瘤患者中的临床意义及其在肿瘤进展中的生物学功能。采用实时定量 RT-PCR 检测 miR-33b 的表达。通过受试者工作特征曲线和 Kaplan-Meier(KM)生存分析评估 miR-33b 的诊断和预后价值。进一步分析 miR-33b 的功能作用。脑胶质瘤患者和细胞中 miR-33b 的表达降低。miR-33b 的表达具有较高的诊断准确性,可预测预后不良。过表达 miR-33b 可抑制脑胶质瘤细胞的增殖、迁移和侵袭。miR-33b 的低表达可作为脑胶质瘤诊断和预后的有前途的生物标志物,可能是一个潜在的治疗靶点。